Factors determining susceptibility to anti-PD-1 treatment seem to be at least partly overlapping between HL and solid tumors as we found an association between expression of CXCL9, CCR5 and PD-L1 with early excellent response. The gene discussed is CCR5; the disease is Hodgkins lymphoma.